Sunday, March 22, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

A conversation with Sam LaCrosse, a self-described nobody

A conversation with Sam LaCrosse, a self-described nobody

We speak with Sam Lacrosse, author of Value Economics: The Study of Identity and a commercial cloud executive at Oracle. Sam LaCrosse is a nobody. He hasn’t done anything amazing. He is not extraordinary or impressive. He doesn’t even have a Wikipedia entry. He’s just an ordinary guy from Cleveland, Ohio, who now lives an ordinary life in Austin, Texas. But if you want to check him out, he writes blogs on dontreadthisblog.com and hosts Don’t Listen to This Podcast. Sam is the CEO and founder of Don’t Do This, LLC, a company that makes no money. He is also a board member of Thrive Living Corporation and an ambassador for RallyCap Sports. This is his first book.

To purchase his latest book, Value Economics: The Study of Identity, please select the following link.

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!